Depletion in native vitamin D: A potential risk factor for hyperparathyroidism and osteomalacia in Algerian hemodialyzed patients;La depletion relative en vitamine D native: Un facteur de risque potentiel chez l'hemodialyse algerien de lesions radiologiques d'hyperparathyroidie et d'osteomalacie independant de la calcitriolemie

Nephrologie

Volumn 18, Issue 2, 1997, Pages 47-52

  Atik, A ^a   Ghazali, A ^b   Achard, J M ^b   Rida, Z ^b   Oprisiu, R ^b   Brazier, M ^c,d   Leflon, P ^c,d   Gueris, J ^e   Moriniere Ph ^b   Sari, Z ^b   Fournier, A ^b,c  

^a BADJI MOKHTAR UNIVERSITY   (Algeria)

^b Serv de Nephrologie Med Int   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e NONE

Author keywords

acidosis; hemodialysis (chronic); hyperparathyroidism; hypocalcemia; osteomalacia; vitamine D

Indexed keywords

VITAMIN D; ALUMINUM; BICARBONATE; CALCIFEDIOL; CALCITRIOL; CALCIUM; PARATHYROID HORMONE;

ADULT; ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; OSTEOMALACIA; RISK FACTOR; ALGERIA; BLOOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOGRAPHY; RENAL REPLACEMENT THERAPY; TIME; VITAMIN D DEFICIENCY;

ADULT; ALGERIA; ALUMINUM; BICARBONATES; CALCIFEDIOL; CALCITRIOL; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOMALACIA; PARATHYROID HORMONE; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; VITAMIN D DEFICIENCY;

EID: 0030623770     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bordier PhJ, Tunchot S, Eastwood JB, Fournier A, De Wardener HE. Lack of histological evidence of vitamin D abnormality in the bone of anephric patients. Clin Sci 1973 ; 44 : 33-41.
2. Fournier A, Boudaillez B, Morinière Ph, Marie A, Sebert JL. Ostéodystrophie rénale. Dans «Vitamines D et maladies des os et du métabolisme minéral». Edité par Fournier A, Garabedian M, Sebert JL, Meunier. Paris : Editions Masson, 1984; 200-46.
3. Fournier A, Morinière Ph, Marie A, El Esper N, Yverneau-Hardy P, Hue P, Ghazali A, Bouzernidj M, Achard JM, Westeel PF, Boudailliez B. Ostéodystrophie rénale, aspects clinico-radiologiques, physiopathologie et traitement. Editions Techniques, Encyclopédie Médico-Chirurgicale (Paris, France) 1994 ; 18 : 043-C-10.
4. Morinière Ph, Cohen-Solal ME, Belbrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL, Fournier A. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake : Emergence of an idiopathic adynamic bone disease not related to aluminium. Nephron 1989 ; 53 : 93-101.
5. Reichel H, Drueke T, Ritz E. Bony complications in chronic renal failure. Oxford Textbook of Clinical Nephrology 1989; 2 : 1365-89.
6. Allain P, Mauras Y. Determination of aluminium in blood, urine and water by inductively coupled plasma emission spectrometry. Analyst Chem 1979; 51 : 2089-95.
7. Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two site immunochemiluminometric assay. J Clin Endocrinol Metab 1987; 65 : 407-14.
8. Wang M, Hercz G, Sherrard DJ, Segre GV, Pei Y. Relationship between intact PTH 1-84 parathyroid hormone and bone histomorphometry parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26 : 836-44.
9. Garabedian M. Méthodes d'étude du métabolisme de la vitamine D chez l'homme. Dans «Vitamine D et maladies des os et du métabolisme minéral». Edité par Fournier A, Garabedian M, Sebert JL, Meunier PJ. Paris : Editions Masson, 1984 ; 41-62.
10. Rubini ME, Coburn JW, Massry SG, Shinaberger JH. Renal osteodystrophy. Some therapeutic considerations relative to long term dialysis and transplantation. Arch Intern Med 1969; 124: 663-8.
11. Cohen ME, Cohen GF, Ahad V, Kaye M. Renal osteodystrophy in patients on chronic hemodialysis. Clin Radiol 1970 ; 21 : 124-8.
12. Mirahamadi KS, Duffy BS, Shinaberger JH, Jowsey J, Massry SG. A controlled evaluation of clinical and metabolic effects of dialysate calcium level during regular dialysis. Trans Am Soc Artif Intern Organs 1971 ; 17 : 118-23.
13. Parfitt AM, Massry SG, Winfield AC, De Palma JR, Gordon A. Disordered calcium and phosphorus metabolism during maintenance hemodialysis : Correlation of clinical, roentgenographic and biochemical changes. Am J Med 1971 ; 51 : 319-23.
14. Tatler GL, Baillard RA, Varghese Z, Young WB, Farrow S, Wills MR, Moorhead JF. Evolution of bone disease over 10 years in 135 patients with terminal renal failure. BMJ 1973 ; 4 : 315-8.
15. Meema HE and Meema S. Microradioscopic bone strucutre of the hand in thyrotoxicose, renal osteodystrophy and acromegaly. Dans : Clinical aspects of metabolic bone disease. Frame B. Editor. Amsterdam : Excerpta Medica, 1973 ; 10-9.
16. Meyrier A, Marsac J, Richet G. The influence of high calcium carbonate intake on bone disease in patient undergoing hemodialysis. Kidney Int 1973 ; 4 : 146-53.
17. Johnson J, Goldsmith RS, Beabout JW, Jowsey J, Kelly PJ, Arnaud M. Prevention and reversal of progresssive secondary hyperparathyroidism in patients maintained by hemodialysis. Am J Med 1974 ; 56 : 827-31.
18. Roussel A. Evaluation à long terme de l'ostéodystrophie rénale des hémodialysés chroniques sans supplément vitaminique D. Thèse de Doctorat en médecine, Faculté de médecine d'Amiens, Université de Picardie, 1982.
19. Remache A. Evaluation du risque d'intoxication par l'aluminium des insuffisants rénaux chroniques en Algérie : analyse des facteurs de risques, étude du retentissement potentiel sur l'os et le système nerveux en cas d'insuffisance rénale avancée. Thèse de Doctorat en sciences médicales. Institut national des Sciences Médicales, Alger, 1994.
20. Slatopolsky E, Finch J, Kubodera K, Nishi Y, Brown A, Morissey J. Hypocalcemia overrides the suppressive effect of both 1,25(OH)2 D3 and its analog 22-oxa-calcitriol on preproPTH mRNA synthesis and PTH secretion in uremia . J Am Soc Nephrol 1993 ; 47 : 23-42.
21. Bayard F, Bec Ph, Ton That H, Louvet JP. Plasma 25 hydroxycholecaliferol in chronic renal failure. Eur J Clin Invest 1973 ; 3 : 447-50.
22. Van der Wielen RPS, Löwik MRH, Van den Berg H, de Groot L, Haller J, Moreiras U, Van Staveren WA. Serum vitamin D concentrations in elderly in Europe. Lancet 1995 ; 346 : 207-10.
23. Lefebvre A, de Vernejoul MC, Gueris J. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989 ; 36 : 1112-8.
24. Morrissey E, Rothstein M, Mayor G, Slatopolsky E. Suppression of parathyroid hormone secretion by aluminium. Kidney Int 1983; 23 : 699-704.
25. Ghazali A, Benhamida F, Bouzernidj M, El Esper N, Westeel PF, Fournier A. Management of hyperphosphatemia in patients with renal failure. Curr Opin Nephrol Hypert 1993 ; 2 : 566-79.
26. Eastwood JB, Harris E, de Wardener HE. Vitamin D deficiency in the osteomalacia of renal failure. Lancet 1976 ; 2 : 1209-11.
27. Fournier A, Bordier Ph, Gueris J, Sebert JL, Marie P, Ferrière C, Bedrossian J, de Luca HF. Comparison of 1-alphahydroxycholecalciferol and 25 hydroxycho-lecalciferol in the treatment of renal osteodystrophy. greater effect of 25 hydrocholecalciferol on bone mineralization. Kidney Int 1979 ; 15 : 196-204.
28. Eastwood JB, Bordier PJ, Clarkson ED, Tunchot S, De Warderner HE. The contrasting effect on bone histology of vitamin D and of calcium corbonate in the osteomalacia of chronic renal failure. Clin Sci Mol Med 1974 ; 47 : 23-42.
29. Fournier A, Morinière Ph, Oprisiu R, Ghazali A, Boudailliez B. 1 alphahydroxyvitamine D3 derivatives in the treatment of renal bone disease. Justifications and optimal modalities of administration. Nephron 1995 ; 71 : 254-83.